Kazune Sigita, Nurka Inga, Zolmanis Matiss, Paulausks Arturs, Bandere Dace
Department of Anesthesiology and Intensive Care, Riga Stradins University, Riga, Latvia.
Department of Anesthesiology, Hospital of Traumatology and Orthopedics, Riga, Latvia.
Local Reg Anesth. 2023 Sep 15;16:143-151. doi: 10.2147/LRA.S425353. eCollection 2023.
The study examined the pharmacokinetic profile of fixed formulation mixtures comprising 225 mg of ropivacaine for local infiltration analgesia with or without epinephrine, and femoral nerve block in older patients presenting for orthopedic surgery and explored potential influences of block type, age, and body weight on this profile.
Twenty four patients scheduled for total knee arthroplasty were randomly assigned to three groups: femoral nerve block, local infiltration analgesia with epinephrine and local infiltration analgesia without epinephrine. Blood samples were collected at 10, 30, 60, and 120 min following the block and total plasma concentrations of ropivacaine were quantified by high performance liquid chromatography.
The mean individual peak total plasma concentrations of ropivacaine in local infiltration analgesia with and without epinephrine, and femoral nerve block group were 0.334, 0.490 and 0.545 μg mL (p = 0.16). Local infiltration with epinephrine group had significantly lower plasma ropivacaine concentrations at 30, 60 and 120 minutes. The plasma ropivacaine concentrations exceeded 2.2 μg mL in one patient. Age, but not body weight, had a moderate correlation with peak plasma ropivacaine concentration (r = 0.37, p = 0.08).
Administration of a fixed 225 mg dose of ropivacaine for local infiltration analgesia with epinephrine and femoral nerve block results in plasma ropivacaine concentrations below the toxicity threshold, indicating their safety. The use of local infiltration analgesia with epinephrine provides a greater safety margin, as local infiltration analgesia without epinephrine may lead to ropivacaine concentrations associated with symptoms of local anesthetic toxicity.
本研究考察了含225mg罗哌卡因的固定制剂混合物用于骨科手术老年患者局部浸润镇痛(加或不加肾上腺素)及股神经阻滞时的药代动力学特征,并探讨了阻滞类型、年龄和体重对该特征的潜在影响。
24例计划行全膝关节置换术的患者被随机分为三组:股神经阻滞组、加肾上腺素局部浸润镇痛组和不加肾上腺素局部浸润镇痛组。在阻滞术后10、30、60和120分钟采集血样,采用高效液相色谱法定量罗哌卡因的血浆总浓度。
加肾上腺素和不加肾上腺素局部浸润镇痛组以及股神经阻滞组罗哌卡因的平均个体血浆总浓度峰值分别为0.334、0.490和0.545μg/mL(p = 0.16)。加肾上腺素局部浸润镇痛组在30、60和120分钟时血浆罗哌卡因浓度显著较低。1例患者血浆罗哌卡因浓度超过2.2μg/mL。年龄与罗哌卡因血浆浓度峰值有中度相关性(r = 0.37,p = 0.08),而体重与罗哌卡因血浆浓度峰值无相关性。
给予固定剂量225mg罗哌卡因用于加肾上腺素局部浸润镇痛及股神经阻滞时,血浆罗哌卡因浓度低于毒性阈值,表明其安全性。加肾上腺素局部浸润镇痛具有更大的安全边际,因为不加肾上腺素局部浸润镇痛可能导致罗哌卡因浓度达到与局部麻醉药毒性症状相关的水平。